Chugai Seiyaku Kabushiki Kaisha

Hiroaki Matsushita

Hidetomo Kitamura

Yoshinobu Higuchi

Yuki Iwayanagi

Keiko Hirokawa

Ryosuke Mihara

Yumi Yamamoto

Akihisa Kaneko

Tomohisa Saito

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

Growing community of inventors

Shizuoka, Japan

Hiroaki Matsushita